Biolife Solutions (BLFS) EBIT (2010 - 2026)

Biolife Solutions (BLFS) has reported EBIT for 17 consecutive years, with $1.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT rose 110.52% year-over-year to $1.7 million in Q2 2026; TTM through Jun 2026 was $3.0 million, a 118.07% increase from a year earlier, with the FY2025 full-year figure at -$16.6 million, down 270.83% from the prior year.
• EBIT was $1.7 million for Q2 2026 at Biolife Solutions, up from $27000.0 in the prior quarter.
• Over five years, EBIT peaked at $90.3 million in Q4 2022 and troughed at -$76.6 million in Q2 2022.
• A 5-year average of -$2.6 million and a median of -$902500.0 in 2024 frame the typical range for EBIT.
• The widest YoY moves for EBIT: up 589.29% in 2022, down 1580.86% in 2022.
• Over 5 years, EBIT stood at $90.3 million in 2022, then sank by 80.6% to $17.5 million in 2023, then plunged by 96.91% to $542000.0 in 2024, then jumped by 148.52% to $1.3 million in 2025, then climbed by 25.91% to $1.7 million in 2026.
• The last three EBIT figures came in at $1.7 million (Q2 2026), $27000.0 (Q1 2026), and $1.3 million (Q4 2025), per Business Quant data.